(MENAFN) Hikma Pharmaceuticals announced posting a 44 percent increase in its profit in the January-June period due to a strong performance in its injectable business in the US, The Peninsula Qatar reported.
The Jordanian drug maker's revenue increased 41 percent, hitting USD346 million, while operating margins in the business was up 41 percent compared to 28.5 percent in the same period last year.
"This reflects exceptionally strong sales from certain market opportunities in the U.S., a focus on higher-value products and tight control of overhead costs across our manufacturing facilities," the company said.
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.